Alembic Pharmaceuticals Secures USFDA Nod for Eye Surgery Drug
Alembic Pharmaceuticals Ltd received final approval from the USFDA for its generic Difluprednate ophthalmic emulsion, used to treat eye inflammation and pain post-surgery. This approval marks a significant step as it matches the therapeutic equivalence of Sandoz Inc's Durezol eye emulsion.
- Country:
- India
Alembic Pharmaceuticals Ltd has achieved a pivotal milestone by obtaining final approval from the US Food & Drug Administration for its generic version of Difluprednate ophthalmic emulsion.
This medication is notably used to manage inflammation and pain subsequent to ocular surgery. The approval confirms its therapeutic equivalence to Durezol ophthalmic emulsion, a product by Sandoz Inc.
The emulsion not only addresses post-surgical discomfort but is also indicated for endogenous anterior uveitis, thereby broadening its scope of application in ophthalmology.
Advertisement
ALSO READ
-
Indoco Remedies gets USFDA nod to market generic epilepsy treatment medicine
-
Biocon Pharma's Milestone: USFDA Approval for Generic Everolimus
-
Alembic Pharma Secures Tentative USFDA Nod for Bosutinib 400 mg Tablets
-
Granules India gets USFDA tentative nod for generic ADHD treatment tablets
-
Granules India gets USFDA tentative nod for generic ADHD treatment tablets
Google News